{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "RGD",
      "SARS-CoV-2",
      "fibrosis",
      "\u03b1V\u03b26"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34132013",
  "DateCompleted": {
    "Year": "2021",
    "Month": "08",
    "Day": "17"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "09",
    "Day": "20"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "06",
        "Day": "15"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1002/cbic.202100209"
    ],
    "Journal": {
      "ISSN": "1439-7633",
      "JournalIssue": {
        "Volume": "22",
        "Issue": "15",
        "PubDate": {
          "Year": "2021",
          "Month": "Aug",
          "Day": "03"
        }
      },
      "Title": "Chembiochem : a European journal of chemical biology",
      "ISOAbbreviation": "Chembiochem"
    },
    "ArticleTitle": "\u03b1<sub>V</sub> \u03b2<sub>6</sub> Integrin: An Intriguing Target for COVID-19 and Related Diseases.",
    "Pagination": {
      "StartPage": "2516",
      "EndPage": "2520",
      "MedlinePgn": "2516-2520"
    },
    "Abstract": {
      "AbstractText": [
        "The outbreak of SARS-CoV-2 has been an extraordinary event that constituted a global health emergency. As the novel coronavirus is continuing to spread over the world, the need for therapeutic agents to control this pandemic is increasing. \u03b1<sub>V</sub> \u03b2<sub>6</sub> Integrin may be an intriguing target not only for the inhibition of SARS-CoV-2 entry, but also for the diagnosis/treatment of COVID-19 related fibrosis, an emerging type of fibrotic disease which will probably affect a significant part of the recovered patients. In this short article, the possible role of this integrin for fighting COVID-19 is discussed on the basis of recently published evidence, showing how its underestimated involvement may be interesting for the development of novel pharmacological tools."
      ],
      "CopyrightInformation": "\u00a9 2021 The Authors. ChemBioChem published by Wiley-VCH GmbH."
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0001-7745-0884"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Dipartimento di Scienze degli Alimenti e del Farmaco, Universit\u00e0 di Parma, Parco Area delle Scienze 27A, 43124, Parma, Italy."
          }
        ],
        "LastName": "Bugatti",
        "ForeName": "Kelly",
        "Initials": "K"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Germany",
    "MedlineTA": "Chembiochem",
    "NlmUniqueID": "100937360",
    "ISSNLinking": "1439-4227"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Integrin beta Chains"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "integrin beta6"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "metabolism",
        "pathology",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "metabolism",
        "pathology",
        "virology"
      ],
      "DescriptorName": "Fibrosis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Integrin beta Chains"
    },
    {
      "QualifierName": [
        "isolation & purification"
      ],
      "DescriptorName": "SARS-CoV-2"
    }
  ],
  "CoiStatement": "The authors declare no conflict of interest."
}